NO324173B1 - 4,5-dihydro-1H-pyrazolderivater med CB1-antagonistaktivitet, fremgangsmate til fremstilling derav, anvendelse derav til fremstilling av et medikament, en farmasoytisk sammensetning og mellomprodukter - Google Patents
4,5-dihydro-1H-pyrazolderivater med CB1-antagonistaktivitet, fremgangsmate til fremstilling derav, anvendelse derav til fremstilling av et medikament, en farmasoytisk sammensetning og mellomprodukter Download PDFInfo
- Publication number
- NO324173B1 NO324173B1 NO20024531A NO20024531A NO324173B1 NO 324173 B1 NO324173 B1 NO 324173B1 NO 20024531 A NO20024531 A NO 20024531A NO 20024531 A NO20024531 A NO 20024531A NO 324173 B1 NO324173 B1 NO 324173B1
- Authority
- NO
- Norway
- Prior art keywords
- phenyl
- chlorophenyl
- pyrazole
- formula
- dihydro
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 11
- 239000003814 drug Substances 0.000 title claims description 7
- 238000000034 method Methods 0.000 title claims description 7
- 229940079593 drug Drugs 0.000 title claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 4
- MCGBIXXDQFWVDW-UHFFFAOYSA-N 4,5-dihydro-1h-pyrazole Chemical class C1CC=NN1 MCGBIXXDQFWVDW-UHFFFAOYSA-N 0.000 title abstract description 5
- 230000000694 effects Effects 0.000 title description 3
- 229940124802 CB1 antagonist Drugs 0.000 title 1
- 239000012450 pharmaceutical intermediate Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 160
- -1 propionyloxy Chemical group 0.000 claims abstract description 23
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 16
- 239000001257 hydrogen Substances 0.000 claims abstract description 16
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 12
- 125000004076 pyridyl group Chemical group 0.000 claims abstract description 11
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims abstract description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 9
- 125000001624 naphthyl group Chemical group 0.000 claims abstract description 8
- 125000001424 substituent group Chemical group 0.000 claims abstract description 8
- 125000001544 thienyl group Chemical group 0.000 claims abstract description 7
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims abstract description 6
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 4
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims abstract description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 3
- 229930003827 cannabinoid Natural products 0.000 claims description 15
- 239000003557 cannabinoid Substances 0.000 claims description 15
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- 150000001412 amines Chemical class 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 8
- 125000006239 protecting group Chemical group 0.000 claims description 8
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 6
- 229910006080 SO2X Inorganic materials 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 208000012902 Nervous system disease Diseases 0.000 claims description 5
- 208000025966 Neurological disease Diseases 0.000 claims description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 208000020016 psychiatric disease Diseases 0.000 claims description 5
- 208000028017 Psychotic disease Diseases 0.000 claims description 4
- 230000005540 biological transmission Effects 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- 210000005036 nerve Anatomy 0.000 claims description 4
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 claims description 3
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 3
- PMFKSNJVULPDBR-UHFFFAOYSA-N 5-(4-chlorophenyl)-n'-(4-fluorophenyl)sulfonyl-4-phenyl-3,4-dihydropyrazole-2-carboximidamide Chemical compound C1=CC(F)=CC=C1S(=O)(=O)NC(=N)N1N=C(C=2C=CC(Cl)=CC=2)C(C=2C=CC=CC=2)C1 PMFKSNJVULPDBR-UHFFFAOYSA-N 0.000 claims description 3
- AXJQVVLKUYCICH-UHFFFAOYSA-N 5-(4-chlorophenyl)-n-(4-chlorophenyl)sulfonyl-n'-methyl-4-phenyl-3,4-dihydropyrazole-2-carboximidamide Chemical compound C1C(C=2C=CC=CC=2)C(C=2C=CC(Cl)=CC=2)=NN1C(=NC)NS(=O)(=O)C1=CC=C(Cl)C=C1 AXJQVVLKUYCICH-UHFFFAOYSA-N 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 208000019901 Anxiety disease Diseases 0.000 claims description 3
- 208000027559 Appetite disease Diseases 0.000 claims description 3
- 206010012289 Dementia Diseases 0.000 claims description 3
- 208000014094 Dystonic disease Diseases 0.000 claims description 3
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 208000026139 Memory disease Diseases 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 3
- 208000016620 Tourette disease Diseases 0.000 claims description 3
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims description 3
- 230000036506 anxiety Effects 0.000 claims description 3
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 3
- 208000015114 central nervous system disease Diseases 0.000 claims description 3
- 230000006735 deficit Effects 0.000 claims description 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 3
- 208000010118 dystonia Diseases 0.000 claims description 3
- 206010015037 epilepsy Diseases 0.000 claims description 3
- 230000002140 halogenating effect Effects 0.000 claims description 3
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 claims description 3
- NONOKGVFTBWRLD-UHFFFAOYSA-N isocyanatosulfanylimino(oxo)methane Chemical compound O=C=NSN=C=O NONOKGVFTBWRLD-UHFFFAOYSA-N 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 3
- UCQFSGCWHRTMGG-UHFFFAOYSA-N pyrazole-1-carboximidamide Chemical compound NC(=N)N1C=CC=N1 UCQFSGCWHRTMGG-UHFFFAOYSA-N 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- NRGOZJYSRXOCFH-UHFFFAOYSA-N 4,5-bis(4-methoxyphenyl)-n'-(4-methoxyphenyl)sulfonyl-3,4-dihydropyrazole-2-carboximidamide Chemical compound C1=CC(OC)=CC=C1C1C(C=2C=CC(OC)=CC=2)=NN(C(=N)NS(=O)(=O)C=2C=CC(OC)=CC=2)C1 NRGOZJYSRXOCFH-UHFFFAOYSA-N 0.000 claims description 2
- RBDSMVUZBCAAEN-UHFFFAOYSA-N 5-(4-chlorophenyl)-4-phenyl-n'-(2,4,6-trimethylphenyl)sulfonyl-3,4-dihydropyrazole-2-carboximidamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC(=N)N1N=C(C=2C=CC(Cl)=CC=2)C(C=2C=CC=CC=2)C1 RBDSMVUZBCAAEN-UHFFFAOYSA-N 0.000 claims description 2
- VHRQDVXOLLGRSP-UHFFFAOYSA-N 5-(4-chlorophenyl)-n'-(4-chlorophenyl)sulfonyl-4-phenyl-n-pyridin-2-yl-3,4-dihydropyrazole-2-carboximidamide Chemical compound C1=CC(Cl)=CC=C1C1=NN(C(\NC=2N=CC=CC=2)=N\S(=O)(=O)C=2C=CC(Cl)=CC=2)CC1C1=CC=CC=C1 VHRQDVXOLLGRSP-UHFFFAOYSA-N 0.000 claims description 2
- OVBPZWWNLXSVAC-UHFFFAOYSA-N 5-(4-chlorophenyl)-n'-(4-chlorophenyl)sulfonyl-n,4-diphenyl-3,4-dihydropyrazole-2-carboximidamide Chemical compound C1=CC(Cl)=CC=C1C1=NN(C(\NC=2C=CC=CC=2)=N\S(=O)(=O)C=2C=CC(Cl)=CC=2)CC1C1=CC=CC=C1 OVBPZWWNLXSVAC-UHFFFAOYSA-N 0.000 claims description 2
- ATGPYUSOVVWMQP-UHFFFAOYSA-N 5-(4-chlorophenyl)-n'-(4-fluorophenyl)sulfonyl-4-hydroxy-4-phenyl-3h-pyrazole-2-carboximidamide Chemical compound C=1C=CC=CC=1C1(O)CN(C(=N)NS(=O)(=O)C=2C=CC(F)=CC=2)N=C1C1=CC=C(Cl)C=C1 ATGPYUSOVVWMQP-UHFFFAOYSA-N 0.000 claims description 2
- XXYLQSSZLZNJAF-UHFFFAOYSA-N 5-(4-chlorophenyl)-n-(4-fluorophenyl)sulfonyl-4-phenyl-n'-propyl-3,4-dihydropyrazole-2-carboximidamide Chemical compound C1C(C=2C=CC=CC=2)C(C=2C=CC(Cl)=CC=2)=NN1C(=NCCC)NS(=O)(=O)C1=CC=C(F)C=C1 XXYLQSSZLZNJAF-UHFFFAOYSA-N 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 2
- 208000028867 ischemia Diseases 0.000 claims description 2
- BQPIGGFYSBELGY-UHFFFAOYSA-N mercury(2+) Chemical class [Hg+2] BQPIGGFYSBELGY-UHFFFAOYSA-N 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- YNTNKIJUFXILJN-UHFFFAOYSA-N n'-(4-fluorophenyl)sulfonyl-4,5-bis(4-methoxyphenyl)-3,4-dihydropyrazole-2-carboximidamide Chemical compound C1=CC(OC)=CC=C1C1C(C=2C=CC(OC)=CC=2)=NN(C(=N)NS(=O)(=O)C=2C=CC(F)=CC=2)C1 YNTNKIJUFXILJN-UHFFFAOYSA-N 0.000 claims description 2
- LOWNRGJMVVHOEY-UHFFFAOYSA-N n-(4-chlorophenyl)sulfonyl-4-phenyl-n'-propan-2-yl-5-pyridin-4-yl-3,4-dihydropyrazole-2-carboximidamide Chemical compound C1C(C=2C=CC=CC=2)C(C=2C=CN=CC=2)=NN1C(=NC(C)C)NS(=O)(=O)C1=CC=C(Cl)C=C1 LOWNRGJMVVHOEY-UHFFFAOYSA-N 0.000 claims description 2
- SCGPTIIGSPSBRD-UHFFFAOYSA-N n-acetamido-5-(4-chlorophenyl)-n'-(4-chlorophenyl)sulfonyl-4-phenyl-3,4-dihydropyrazole-2-carboximidamide Chemical compound C1C(C=2C=CC=CC=2)C(C=2C=CC(Cl)=CC=2)=NN1C(/NNC(=O)C)=N/S(=O)(=O)C1=CC=C(Cl)C=C1 SCGPTIIGSPSBRD-UHFFFAOYSA-N 0.000 claims description 2
- 125000005034 trifluormethylthio group Chemical group FC(S*)(F)F 0.000 claims description 2
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 claims description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 1
- RKVDQNXSXIWCQP-UHFFFAOYSA-N 5-(4-chlorophenyl)-n'-(4-chlorophenyl)sulfonyl-n-(dimethylamino)-4-phenyl-3,4-dihydropyrazole-2-carboximidamide Chemical compound C1C(C=2C=CC=CC=2)C(C=2C=CC(Cl)=CC=2)=NN1C(/NN(C)C)=N\S(=O)(=O)C1=CC=C(Cl)C=C1 RKVDQNXSXIWCQP-UHFFFAOYSA-N 0.000 claims 1
- CXNXHKUCYNGGIR-UHFFFAOYSA-N 5-(4-chlorophenyl)-n-(4-chlorophenyl)sulfonyl-n'-methyl-4-pyridin-4-yl-3,4-dihydropyrazole-2-carboximidamide Chemical compound C1C(C=2C=CN=CC=2)C(C=2C=CC(Cl)=CC=2)=NN1C(=NC)NS(=O)(=O)C1=CC=C(Cl)C=C1 CXNXHKUCYNGGIR-UHFFFAOYSA-N 0.000 claims 1
- MXVJHHZCQUGIBP-UHFFFAOYSA-N 5-(4-chlorophenyl)-n-(4-chlorophenyl)sulfonyl-n-ethyl-4-hydroxy-4-phenyl-3h-pyrazole-2-carboximidamide Chemical compound C=1C=C(Cl)C=CC=1S(=O)(=O)N(CC)C(=N)N(N=1)CC(O)(C=2C=CC=CC=2)C=1C1=CC=C(Cl)C=C1 MXVJHHZCQUGIBP-UHFFFAOYSA-N 0.000 claims 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 claims 1
- PYXYWJZSZZCOFU-UHFFFAOYSA-N n-(4-chlorophenyl)sulfonyl-5-(5-chlorothiophen-2-yl)-n'-methyl-4-phenyl-3,4-dihydropyrazole-2-carboximidamide Chemical compound C1C(C=2C=CC=CC=2)C(C=2SC(Cl)=CC=2)=NN1C(=NC)NS(=O)(=O)C1=CC=C(Cl)C=C1 PYXYWJZSZZCOFU-UHFFFAOYSA-N 0.000 claims 1
- OKBRZVYBUMLZRR-UHFFFAOYSA-N n-[5-(4-chlorophenyl)-4-phenyl-3,4-dihydropyrazole-2-carboximidoyl]-n-methyl-3-(trifluoromethyl)benzamide Chemical compound C=1C=CC(C(F)(F)F)=CC=1C(=O)N(C)C(=N)N(N=1)CC(C=2C=CC=CC=2)C=1C1=CC=C(Cl)C=C1 OKBRZVYBUMLZRR-UHFFFAOYSA-N 0.000 claims 1
- QNYKEYVDTHEXKV-UHFFFAOYSA-N n-[amino-[5-(4-chlorophenyl)-4-phenyl-3,4-dihydropyrazol-2-yl]methylidene]pyridine-2-carboxamide Chemical compound C1=CC(Cl)=CC=C1C1=NN(C(=N)NC(=O)C=2N=CC=CC=2)CC1C1=CC=CC=C1 QNYKEYVDTHEXKV-UHFFFAOYSA-N 0.000 claims 1
- 230000005062 synaptic transmission Effects 0.000 claims 1
- 239000005557 antagonist Substances 0.000 abstract description 5
- 230000003389 potentiating effect Effects 0.000 abstract description 3
- 240000004308 marijuana Species 0.000 abstract 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 abstract 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 56
- 230000008018 melting Effects 0.000 description 48
- 238000002844 melting Methods 0.000 description 48
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 42
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 42
- 238000006243 chemical reaction Methods 0.000 description 32
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 239000000203 mixture Substances 0.000 description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- 239000003208 petroleum Substances 0.000 description 8
- SKLKZKAMWPQZLM-UHFFFAOYSA-N 3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1h-pyrazole Chemical compound C1=CC(Cl)=CC=C1C1=NNCC1C1=CC=CC=C1 SKLKZKAMWPQZLM-UHFFFAOYSA-N 0.000 description 7
- 238000003818 flash chromatography Methods 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 229940044551 receptor antagonist Drugs 0.000 description 6
- 239000002464 receptor antagonist Substances 0.000 description 6
- 239000012258 stirred mixture Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 4
- 108050007331 Cannabinoid receptor Proteins 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000003495 polar organic solvent Substances 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- GHPPZVCTAFMRFC-UHFFFAOYSA-N 2-[5-(4-chlorophenyl)-4-phenyl-3,4-dihydropyrazol-2-yl]ethanamine Chemical compound N=1N(CCN)CC(C=2C=CC=CC=2)C=1C1=CC=C(Cl)C=C1 GHPPZVCTAFMRFC-UHFFFAOYSA-N 0.000 description 2
- XPJPCDIVXGVHLY-UHFFFAOYSA-N 5-(4-chlorophenyl)-4-phenyl-3,4-dihydropyrazole-2-carboximidamide Chemical compound N=1N(C(=N)N)CC(C=2C=CC=CC=2)C=1C1=CC=C(Cl)C=C1 XPJPCDIVXGVHLY-UHFFFAOYSA-N 0.000 description 2
- ZUOBXCIPMDWWFZ-UHFFFAOYSA-N 5-(4-chlorophenyl)-n-(4-chlorophenyl)sulfonyl-4-phenyl-3,4-dihydropyrazole-2-carboxamide Chemical compound C1=CC(Cl)=CC=C1C1=NN(C(=O)NS(=O)(=O)C=2C=CC(Cl)=CC=2)CC1C1=CC=CC=C1 ZUOBXCIPMDWWFZ-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 239000000010 aprotic solvent Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- OJURWUUOVGOHJZ-UHFFFAOYSA-N methyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-(2-methoxy-2-oxoethyl)amino]ethyl]amino]acetate Chemical compound C=1C=CC=C(OC(C)=O)C=1CN(CC(=O)OC)CCN(CC(=O)OC)CC1=CC=CC=C1OC(C)=O OJURWUUOVGOHJZ-UHFFFAOYSA-N 0.000 description 2
- CJHMNJCPDWKHIJ-UHFFFAOYSA-N methyl 5-(4-chlorophenyl)-n-(4-chlorophenyl)sulfonyl-4-phenyl-3,4-dihydropyrazole-2-carboximidothioate Chemical compound C1C(C=2C=CC=CC=2)C(C=2C=CC(Cl)=CC=2)=NN1C(SC)=NS(=O)(=O)C1=CC=C(Cl)C=C1 CJHMNJCPDWKHIJ-UHFFFAOYSA-N 0.000 description 2
- FCMYFMSWNFVHAC-UHFFFAOYSA-N methyl n-(4-chlorophenyl)sulfonylcarbamate Chemical compound COC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 FCMYFMSWNFVHAC-UHFFFAOYSA-N 0.000 description 2
- SCJVBJZQVUMHTE-UHFFFAOYSA-N n-[amino-[5-(4-chlorophenyl)-4-phenyl-3,4-dihydropyrazol-2-yl]methylidene]naphthalene-1-carboxamide Chemical compound C=1C=CC2=CC=CC=C2C=1C(=O)N=C(N)N(N=1)CC(C=2C=CC=CC=2)C=1C1=CC=C(Cl)C=C1 SCJVBJZQVUMHTE-UHFFFAOYSA-N 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- QDNFIYLWAMNCGV-UHFFFAOYSA-N 1-[5-(4-chlorophenyl)-4-phenyl-3,4-dihydropyrazol-2-yl]-3-(4-chlorophenyl)sulfonylbutan-1-one Chemical compound C=1C=C(Cl)C=CC=1S(=O)(=O)C(C)CC(=O)N(N=1)CC(C=2C=CC=CC=2)C=1C1=CC=C(Cl)C=C1 QDNFIYLWAMNCGV-UHFFFAOYSA-N 0.000 description 1
- JTPNRXUCIXHOKM-UHFFFAOYSA-N 1-chloronaphthalene Chemical compound C1=CC=C2C(Cl)=CC=CC2=C1 JTPNRXUCIXHOKM-UHFFFAOYSA-N 0.000 description 1
- YBMMBGKWEDRYNB-UHFFFAOYSA-N 2-(2-benzylsulfonylethyl)-5-(4-chlorophenyl)-4-phenyl-3,4-dihydropyrazole Chemical compound C1=CC(Cl)=CC=C1C(C(C1)C=2C=CC=CC=2)=NN1CCS(=O)(=O)CC1=CC=CC=C1 YBMMBGKWEDRYNB-UHFFFAOYSA-N 0.000 description 1
- FGCBXTLVUQGHQP-UHFFFAOYSA-N 3,4-dihydropyrazole-2-carboxamide Chemical class NC(=O)N1CCC=N1 FGCBXTLVUQGHQP-UHFFFAOYSA-N 0.000 description 1
- BMKMVBXDEAVUTE-UHFFFAOYSA-N 3,4-dihydropyrazole-2-carboximidamide Chemical class NC(=N)N1CCC=N1 BMKMVBXDEAVUTE-UHFFFAOYSA-N 0.000 description 1
- GAZRNXIMWKZADY-UHFFFAOYSA-N 3,5-dimethylpyrazole-1-carboximidamide Chemical compound CC=1C=C(C)N(C(N)=N)N=1 GAZRNXIMWKZADY-UHFFFAOYSA-N 0.000 description 1
- WSWMNIYBLWKIRE-UHFFFAOYSA-N 3-(4-chlorophenyl)-2-(3-methylphenyl)sulfonyl-4-phenylpyrazolidine-1-carboximidamide Chemical compound CC1=CC=CC(S(=O)(=O)N2N(CC(C2C=2C=CC(Cl)=CC=2)C=2C=CC=CC=2)C(N)=N)=C1 WSWMNIYBLWKIRE-UHFFFAOYSA-N 0.000 description 1
- PTKMGIYABHEVJU-UHFFFAOYSA-N 3-(4-chlorophenyl)-4-phenyl-1,5-dihydropyrazol-4-ol Chemical compound C=1C=CC=CC=1C1(O)CNN=C1C1=CC=C(Cl)C=C1 PTKMGIYABHEVJU-UHFFFAOYSA-N 0.000 description 1
- ISSOITWPLPETPZ-UHFFFAOYSA-N 3-(4-chlorophenyl)-4-phenyl-1,5-dihydropyrazol-4-ol;(4-chlorophenyl)-(2-phenyloxiran-2-yl)methanone Chemical compound C1=CC(Cl)=CC=C1C(=O)C1(C=2C=CC=CC=2)OC1.C=1C=CC=CC=1C1(O)CNN=C1C1=CC=C(Cl)C=C1 ISSOITWPLPETPZ-UHFFFAOYSA-N 0.000 description 1
- NPUIQANQRDIHLU-UHFFFAOYSA-N 3-(4-chlorophenyl)sulfonylbutanoic acid Chemical compound OC(=O)CC(C)S(=O)(=O)C1=CC=C(Cl)C=C1 NPUIQANQRDIHLU-UHFFFAOYSA-N 0.000 description 1
- SMGRKVJWSIFNAV-UHFFFAOYSA-N 3-(benzenesulfonyl)-1-[5-(4-chlorophenyl)-4-phenyl-3,4-dihydropyrazol-2-yl]propan-1-one Chemical compound C1=CC(Cl)=CC=C1C1=NN(C(=O)CCS(=O)(=O)C=2C=CC=CC=2)CC1C1=CC=CC=C1 SMGRKVJWSIFNAV-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- ONCAZCNPWWQQMW-UHFFFAOYSA-N 3-(trifluoromethyl)benzenesulfonyl chloride Chemical compound FC(F)(F)C1=CC=CC(S(Cl)(=O)=O)=C1 ONCAZCNPWWQQMW-UHFFFAOYSA-N 0.000 description 1
- TUNQKHXTTHRRAB-UHFFFAOYSA-N 3-(trifluoromethyl)benzoyl isothiocyanate Chemical compound FC(F)(F)C1=CC=CC(C(=O)N=C=S)=C1 TUNQKHXTTHRRAB-UHFFFAOYSA-N 0.000 description 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- BFXHJFKKRGVUMU-UHFFFAOYSA-N 4-fluorobenzenesulfonyl chloride Chemical compound FC1=CC=C(S(Cl)(=O)=O)C=C1 BFXHJFKKRGVUMU-UHFFFAOYSA-N 0.000 description 1
- WSSNYTBIOIYFRD-UHFFFAOYSA-N 5-(4-chlorophenyl)-2-[2-(4-chlorophenyl)sulfonylethyl]-4-phenyl-3,4-dihydropyrazole Chemical compound C1=CC(Cl)=CC=C1C(C(C1)C=2C=CC=CC=2)=NN1CCS(=O)(=O)C1=CC=C(Cl)C=C1 WSSNYTBIOIYFRD-UHFFFAOYSA-N 0.000 description 1
- BGXHPWVQZDLJHI-UHFFFAOYSA-N 5-(4-chlorophenyl)-2-[2-(4-chlorophenyl)sulfonylethyl]-4-phenyl-3h-pyrazol-4-ol Chemical compound N1=C(C=2C=CC(Cl)=CC=2)C(O)(C=2C=CC=CC=2)CN1CCS(=O)(=O)C1=CC=C(Cl)C=C1 BGXHPWVQZDLJHI-UHFFFAOYSA-N 0.000 description 1
- CCXWULHEPDRGMF-UHFFFAOYSA-N 5-(4-chlorophenyl)-n'-(4-chlorophenyl)sulfonyl-4-phenyl-n-pyridin-4-yl-3,4-dihydropyrazole-2-carboximidamide Chemical compound C1=CC(Cl)=CC=C1C1=NN(C(\NC=2C=CN=CC=2)=N\S(=O)(=O)C=2C=CC(Cl)=CC=2)CC1C1=CC=CC=C1 CCXWULHEPDRGMF-UHFFFAOYSA-N 0.000 description 1
- FAZVAFJOHIBNSU-UHFFFAOYSA-N 5-(4-chlorophenyl)-n'-methyl-4-phenyl-n-propan-2-ylsulfonyl-3,4-dihydropyrazole-2-carboximidamide Chemical compound N=1N(C(NS(=O)(=O)C(C)C)=NC)CC(C=2C=CC=CC=2)C=1C1=CC=C(Cl)C=C1 FAZVAFJOHIBNSU-UHFFFAOYSA-N 0.000 description 1
- WNHXVUIPVMASEZ-UHFFFAOYSA-N 5-(4-chlorophenyl)-n-(2,4-difluorophenyl)sulfonyl-n'-methyl-4-phenyl-3,4-dihydropyrazole-2-carboximidamide Chemical compound C1C(C=2C=CC=CC=2)C(C=2C=CC(Cl)=CC=2)=NN1C(=NC)NS(=O)(=O)C1=CC=C(F)C=C1F WNHXVUIPVMASEZ-UHFFFAOYSA-N 0.000 description 1
- JXUCAZVXNNKWLS-UHFFFAOYSA-N 5-(4-chlorophenyl)-n-(3-chlorophenyl)sulfonyl-n'-methyl-4-phenyl-3,4-dihydropyrazole-2-carboximidamide Chemical compound C1C(C=2C=CC=CC=2)C(C=2C=CC(Cl)=CC=2)=NN1C(=N/C)/NS(=O)(=O)C1=CC=CC(Cl)=C1 JXUCAZVXNNKWLS-UHFFFAOYSA-N 0.000 description 1
- QHICGXYKYYCCKA-UHFFFAOYSA-N 5-(4-chlorophenyl)-n-(4-chlorophenyl)sulfonyl-4-phenyl-3,4-dihydropyrazole-2-carboximidoyl chloride Chemical compound C1C(C=2C=CC=CC=2)C(C=2C=CC(Cl)=CC=2)=NN1C(Cl)=NS(=O)(=O)C1=CC=C(Cl)C=C1 QHICGXYKYYCCKA-UHFFFAOYSA-N 0.000 description 1
- YSOLAZQGLFVSLS-UHFFFAOYSA-N 5-(4-chlorophenyl)-n-(4-chlorophenyl)sulfonyl-n'-ethyl-4-hydroxy-4-phenyl-3h-pyrazole-2-carboximidamide Chemical compound C1C(O)(C=2C=CC=CC=2)C(C=2C=CC(Cl)=CC=2)=NN1C(=NCC)NS(=O)(=O)C1=CC=C(Cl)C=C1 YSOLAZQGLFVSLS-UHFFFAOYSA-N 0.000 description 1
- AYYMXSJOWFVFIO-UHFFFAOYSA-N 5-(4-chlorophenyl)-n-(4-chlorophenyl)sulfonyl-n'-ethyl-4-phenyl-3,4-dihydropyrazole-2-carboximidamide Chemical compound C1C(C=2C=CC=CC=2)C(C=2C=CC(Cl)=CC=2)=NN1C(=NCC)NS(=O)(=O)C1=CC=C(Cl)C=C1 AYYMXSJOWFVFIO-UHFFFAOYSA-N 0.000 description 1
- NVJVDZMNNYMORJ-UHFFFAOYSA-N 5-(4-chlorophenyl)-n-(4-chlorophenyl)sulfonyl-n'-methyl-4-pyridin-3-yl-3,4-dihydropyrazole-2-carboximidamide Chemical compound C1C(C=2C=NC=CC=2)C(C=2C=CC(Cl)=CC=2)=NN1C(NC)=NS(=O)(=O)C1=CC=C(Cl)C=C1 NVJVDZMNNYMORJ-UHFFFAOYSA-N 0.000 description 1
- YZLPWYAHNMXZGM-UHFFFAOYSA-N 5-(4-chlorophenyl)-n-(4-fluorophenyl)sulfonyl-4-phenyl-n'-propan-2-yl-3,4-dihydropyrazole-2-carboximidamide Chemical compound C1C(C=2C=CC=CC=2)C(C=2C=CC(Cl)=CC=2)=NN1C(=NC(C)C)NS(=O)(=O)C1=CC=C(F)C=C1 YZLPWYAHNMXZGM-UHFFFAOYSA-N 0.000 description 1
- 241000722948 Apocynum cannabinum Species 0.000 description 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 102000009135 CB2 Cannabinoid Receptor Human genes 0.000 description 1
- 108010073376 CB2 Cannabinoid Receptor Proteins 0.000 description 1
- 102100036214 Cannabinoid receptor 2 Human genes 0.000 description 1
- 229940122820 Cannabinoid receptor antagonist Drugs 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000008697 Cannabis sativa Nutrition 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- 235000015928 Hibiscus cannabinus Nutrition 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000027520 Somatoform disease Diseases 0.000 description 1
- JHOTYHDSLIUKCJ-UHFFFAOYSA-N [6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-3-indolyl]-(4-methoxyphenyl)methanone Chemical group C1=CC(OC)=CC=C1C(=O)C(C1=CC=C(I)C=C11)=C(C)N1CCN1CCOCC1 JHOTYHDSLIUKCJ-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 150000001541 aziridines Chemical class 0.000 description 1
- BXUMISWXFKCEIA-UHFFFAOYSA-N benzyl (ne)-n-[amino(pyrazol-1-yl)methylidene]carbamate Chemical compound C1=CC=NN1C(N)=NC(=O)OCC1=CC=CC=C1 BXUMISWXFKCEIA-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003536 cannabinoid receptor antagonist Substances 0.000 description 1
- 229940065144 cannabinoids Drugs 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 1
- RCTYPNKXASFOBE-UHFFFAOYSA-M chloromercury Chemical compound [Hg]Cl RCTYPNKXASFOBE-UHFFFAOYSA-M 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229960003750 ethyl chloride Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- LFXAECSQJSRSTP-UHFFFAOYSA-N hydron;methyl carbamimidothioate;iodide Chemical compound I.CSC(N)=N LFXAECSQJSRSTP-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005567 liquid scintillation counting Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- LWJROJCJINYWOX-UHFFFAOYSA-L mercury dichloride Chemical compound Cl[Hg]Cl LWJROJCJINYWOX-UHFFFAOYSA-L 0.000 description 1
- CYEBJEDOHLIWNP-UHFFFAOYSA-N methanethioamide Chemical class NC=S CYEBJEDOHLIWNP-UHFFFAOYSA-N 0.000 description 1
- SDDKIZNHOCEXTF-UHFFFAOYSA-N methyl carbamimidothioate Chemical compound CSC(N)=N SDDKIZNHOCEXTF-UHFFFAOYSA-N 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- HLKNXPDTYQPHFF-UHFFFAOYSA-N n-[2-[5-(4-chlorophenyl)-4-phenyl-3,4-dihydropyrazol-2-yl]ethyl]-3-(trifluoromethyl)benzenesulfonamide Chemical compound FC(F)(F)C1=CC=CC(S(=O)(=O)NCCN2N=C(C(C2)C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 HLKNXPDTYQPHFF-UHFFFAOYSA-N 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 208000027753 pain disease Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- JZCPYUJPEARBJL-UHFFFAOYSA-N rimonabant Chemical group CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- VBYPJHLRWKGNAI-UHFFFAOYSA-N tert-butyl aziridine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC1 VBYPJHLRWKGNAI-UHFFFAOYSA-N 0.000 description 1
- WKTORZDXEUASJZ-UHFFFAOYSA-N tert-butyl n-[2-[5-(4-chlorophenyl)-4-phenyl-3,4-dihydropyrazol-2-yl]ethyl]carbamate Chemical compound N=1N(CCNC(=O)OC(C)(C)C)CC(C=2C=CC=CC=2)C=1C1=CC=C(Cl)C=C1 WKTORZDXEUASJZ-UHFFFAOYSA-N 0.000 description 1
- IGSFMHYSWZUENI-UHFFFAOYSA-N tert-butyl n-[amino(pyrazol-1-yl)methylidene]carbamate Chemical compound CC(C)(C)OC(=O)N=C(N)N1C=CC=N1 IGSFMHYSWZUENI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D231/08—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen or sulfur atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL1014728 | 2000-03-23 | ||
| EP00201032 | 2000-03-23 | ||
| PCT/EP2001/003247 WO2001070700A1 (fr) | 2000-03-23 | 2001-03-22 | Derives de 4,5-dihydro-1h-pyrazole ayant une activite antagoniste de cb¿1? |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20024531D0 NO20024531D0 (no) | 2002-09-20 |
| NO20024531L NO20024531L (no) | 2002-11-19 |
| NO324173B1 true NO324173B1 (no) | 2007-09-03 |
Family
ID=26072029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20024531A NO324173B1 (no) | 2000-03-23 | 2002-09-20 | 4,5-dihydro-1H-pyrazolderivater med CB1-antagonistaktivitet, fremgangsmate til fremstilling derav, anvendelse derav til fremstilling av et medikament, en farmasoytisk sammensetning og mellomprodukter |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US6476060B2 (fr) |
| EP (1) | EP1268435B1 (fr) |
| JP (1) | JP2004500401A (fr) |
| KR (1) | KR100800277B1 (fr) |
| CN (1) | CN1205188C (fr) |
| AT (1) | ATE346047T1 (fr) |
| AU (2) | AU4250101A (fr) |
| BR (1) | BR0109457A (fr) |
| CA (1) | CA2401832C (fr) |
| CY (1) | CY1105967T1 (fr) |
| DE (1) | DE60124685T2 (fr) |
| DK (1) | DK1268435T3 (fr) |
| DZ (1) | DZ3335A1 (fr) |
| ES (1) | ES2272449T3 (fr) |
| HK (1) | HK1052349B (fr) |
| HU (1) | HUP0204519A3 (fr) |
| IL (2) | IL151452A0 (fr) |
| MX (1) | MXPA02009258A (fr) |
| NO (1) | NO324173B1 (fr) |
| PL (1) | PL208098B1 (fr) |
| PT (1) | PT1268435E (fr) |
| RU (1) | RU2245878C2 (fr) |
| SI (1) | SI1268435T1 (fr) |
| SK (1) | SK287074B6 (fr) |
| UA (1) | UA74367C2 (fr) |
| WO (1) | WO2001070700A1 (fr) |
Families Citing this family (131)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ2003698A3 (cs) * | 2001-03-22 | 2003-06-18 | Solvay Pharmaceuticals B. V. | 4,5-Dihydro-1H-pyrazolové deriváty mající CB1-antagonistickou účinnost |
| US20050054730A1 (en) * | 2001-03-27 | 2005-03-10 | The Regents Of The University Of California | Compounds, compositions and treatment of oleoylethanolamide-like modulators of PPARalpha |
| PL368441A1 (en) | 2001-09-21 | 2005-03-21 | Solvay Pharmaceuticals B.V. | Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
| WO2003026648A1 (fr) | 2001-09-21 | 2003-04-03 | Solvay Pharmaceuticals B.V. | Derives 4,5-dihydro-1h-pyrazole presentant une puissante activite antagoniste du recepteur cb1 |
| TWI231757B (en) | 2001-09-21 | 2005-05-01 | Solvay Pharm Bv | 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
| NZ534757A (en) | 2002-03-12 | 2006-07-28 | Merck & Co Inc | Substituted amides |
| US6825209B2 (en) | 2002-04-15 | 2004-11-30 | Research Triangle Institute | Compounds having unique CB1 receptor binding selectivity and methods for their production and use |
| GB0216700D0 (en) | 2002-07-18 | 2002-08-28 | Astrazeneca Ab | Process |
| EP1532132B1 (fr) * | 2002-07-29 | 2008-03-19 | F.Hoffmann-La Roche Ag | Nouveaux benzodioxoles |
| US7765162B2 (en) * | 2002-10-07 | 2010-07-27 | Mastercard International Incorporated | Method and system for conducting off-line and on-line pre-authorized payment transactions |
| BR0314872A (pt) * | 2002-10-18 | 2005-08-02 | Pfizer Prod Inc | Ligandos do receptor canabinóide e usos dos mesmos |
| US7129239B2 (en) * | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
| US7247628B2 (en) * | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| MXPA05007114A (es) | 2003-01-02 | 2005-08-26 | Hoffmann La Roche | Nuevos agonistas inversos del receptor cb1. |
| JP4271660B2 (ja) | 2003-01-02 | 2009-06-03 | エフ．ホフマン−ラ ロシュ アーゲー | ピロリル−チアゾール及びｃｂ１受容体逆作動物質としてのその使用 |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| US7329658B2 (en) * | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| GB0302673D0 (en) | 2003-02-06 | 2003-03-12 | Astrazeneca Ab | Pharmaceutical formulations |
| US7176210B2 (en) * | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| US20040214856A1 (en) * | 2003-04-23 | 2004-10-28 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| US7141669B2 (en) * | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
| US7268133B2 (en) * | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
| US7145012B2 (en) * | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| EP1622876A1 (fr) * | 2003-05-07 | 2006-02-08 | Pfizer Products Inc. | Ligands de recepteurs cannabinoides et leurs applications |
| US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| GB0314049D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| WO2004111033A1 (fr) * | 2003-06-18 | 2004-12-23 | Astrazeneca Ab | Agents therapeutiques |
| US20040259887A1 (en) * | 2003-06-18 | 2004-12-23 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| GB0314057D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0314261D0 (en) * | 2003-06-19 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| EP1638556B1 (fr) | 2003-06-20 | 2008-04-02 | F. Hoffmann-La Roche Ag | 2-aminobenzothiazoles utilises comme agonistes inverses du recepteur cb1 |
| WO2005020992A1 (fr) * | 2003-09-02 | 2005-03-10 | Solvay Pharmaceuticals Gmbh | Nouvelles utilisations medicales d'antagonistes selectifs du recepteur cb1 |
| TW200511990A (en) * | 2003-09-02 | 2005-04-01 | Solvay Pharm Gmbh | Novel medical uses of 4, 5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
| US20050239859A2 (en) * | 2003-09-03 | 2005-10-27 | Solvay Pharmaceuticals Gmbh | Novel medical uses of 4,5-dihydro-1h-pyrazole derivatives having cb1- antagonistic activity |
| TW200528102A (en) * | 2003-10-24 | 2005-09-01 | Solvay Pharm Gmbh | Novel medical combination treatment of obesity involving 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
| US20050124660A1 (en) * | 2003-10-27 | 2005-06-09 | Jochen Antel | Novel medical uses of compounds showing CB1-antagonistic activity and combination treatment involving said compounds |
| US20050143441A1 (en) * | 2003-10-27 | 2005-06-30 | Jochen Antel | Novel medical combination treatment of obesity involving 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity |
| GB0327331D0 (en) * | 2003-11-25 | 2003-12-31 | Astrazeneca Ab | Therapeutic agents |
| JP4527729B2 (ja) | 2003-12-08 | 2010-08-18 | エフ．ホフマン−ラ ロシュ アーゲー | 新規チアゾール誘導体 |
| KR100843023B1 (ko) | 2004-01-28 | 2008-07-01 | 에프. 호프만-라 로슈 아게 | 스피로-5환 화합물 |
| JP4693787B2 (ja) * | 2004-01-30 | 2011-06-01 | アボツト・ヘルスケア・プロダクツ・ベー・ブイ | Ｃｂ１拮抗活性を有する１，３，５−三置換４，５−ジヒドロ−１ｈ−ピラゾール誘導体 |
| US7745476B2 (en) | 2004-01-30 | 2010-06-29 | Solvay Pharmaceuticals B.V. | 1,3,5-trisubstituted 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity |
| TW200533657A (en) | 2004-02-17 | 2005-10-16 | Esteve Labor Dr | Substituted pyrazoline compounds, their preparation and use as medicaments |
| GB0403780D0 (en) * | 2004-02-20 | 2004-03-24 | Astrazeneca Ab | Therapeutic agents |
| US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
| EP1735287A1 (fr) * | 2004-04-03 | 2006-12-27 | Astrazeneca AB | Agents therapeutiques |
| CA2564986A1 (fr) | 2004-05-10 | 2005-11-17 | F. Hoffmann-La Roche Ag | Amides pyrroles ou imidazoles destines au traitement de l'obesite |
| ITMI20041033A1 (it) * | 2004-05-24 | 2004-08-24 | Neuroscienze S C A R L | Composti farmaceutici |
| ITMI20041032A1 (it) * | 2004-05-24 | 2004-08-24 | Neuroscienze S C A R L | Compositi farmaceutici |
| TW200602314A (en) | 2004-05-28 | 2006-01-16 | Tanabe Seiyaku Co | A novel pyrrolidine compound and a process for preparing the same |
| US20060025448A1 (en) | 2004-07-22 | 2006-02-02 | Cadila Healthcare Limited | Hair growth stimulators |
| JP2008514718A (ja) * | 2004-09-29 | 2008-05-08 | シェーリング コーポレイション | 置換アゼチドノンおよびｃｂ１アンタゴニストの組み合わせ |
| MX2007004889A (es) | 2004-10-25 | 2007-09-11 | Solvay Pharm Gmbh | Composiciones farmaceuticas que comprenden antagonistas del receptor cannabinoide cb1 y activadores de canales de potasio para el tratamiento de la diabetes mellitus tipo i, la obesidad y trastornos relacionados. |
| KR100912146B1 (ko) | 2004-10-27 | 2009-08-14 | 에프. 호프만-라 로슈 아게 | 인돌 또는 벤즈이미다졸 유도체 |
| EP1812418B1 (fr) | 2004-11-09 | 2010-10-27 | F. Hoffmann-La Roche AG | Derives dibenzosuberone |
| WO2006060211A2 (fr) * | 2004-11-30 | 2006-06-08 | Bayer Pharmaceuticals Corporation | Derives de pyrazole pour le traitement de dysfonctionnement sexuel |
| WO2006060192A2 (fr) * | 2004-11-30 | 2006-06-08 | Bayer Pharmaceuticals Corporation | Derives de pyrazole |
| WO2006060201A2 (fr) * | 2004-11-30 | 2006-06-08 | Bayer Pharmaceuticals Corporation | Derives de pyrazole utilises dans le traitement de troubles psychiatriques |
| WO2006060186A2 (fr) * | 2004-11-30 | 2006-06-08 | Bayer Pharmaceuticals Corporation | Derives de pyrazole pour le traitement de la demence et de troubles associes |
| WO2006106054A1 (fr) | 2005-04-06 | 2006-10-12 | F. Hoffmann-La Roche Ag | Derives de pyridine-3-carboxamide utilises comme agonistes inverses des cb1 |
| WO2006129193A2 (fr) * | 2005-05-27 | 2006-12-07 | Pfizer Products Inc. | Polytherapie pour le traitement de l'obesite ou le maintien du poids apres une perte ponderale |
| US7923465B2 (en) | 2005-06-02 | 2011-04-12 | Glenmark Pharmaceuticals S.A. | Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
| CA2613678A1 (fr) | 2005-06-02 | 2006-12-07 | Glenmark Pharmaceuticals S.A. | Nouveaux ligands des recepteurs des cannabinoides, compositions pharmaceutiques contenant ces ligands, et procede servant a leur preparation |
| EP1743892A1 (fr) | 2005-07-15 | 2007-01-17 | Laboratorios del Dr. Esteve S.A. | Composés pyrazoline substitués, leur préparation et utilisation comme médicaments |
| EP1749820A1 (fr) * | 2005-07-15 | 2007-02-07 | Laboratorios Del Dr. Esteve, S.A. | Sels de dérives pyrazoline, leur préparation et leur utilisation comme medicaments médicaments |
| ES2326460B1 (es) * | 2005-07-15 | 2010-04-19 | Laboratorios Del Dr. Esteve, S.A. | Sales de amonio cuaternario de compuestos de pirazolina sustituidos, su preparacion y uso como medicamentos. |
| EP1749526A1 (fr) * | 2005-07-15 | 2007-02-07 | Laboratorios Del Dr. Esteve, S.A. | Utilisation des derivés de la pyrazoline pour le traitement des troubles alimentaires, comme l'obesité ou le syndrome métabolique chez les patients diabetiques |
| ES2326725B1 (es) * | 2005-07-15 | 2010-05-11 | Laboratorios Del Dr. Esteve, S.A. | Uso de compuestos de pirazolina sustituidos para el tratamiento de trastornos alimentarios, que incluyen la obesidad o el sindrome metabolico en pacientes con diabetes desarrollada. |
| WO2007009690A1 (fr) * | 2005-07-15 | 2007-01-25 | Laboratorios Del Dr. Esteve, S.A | Composes de pyrazoline a substitution heterocyclyle, preparation et utilisation de ceux-ci comme medicaments |
| EP1743890A1 (fr) * | 2005-07-15 | 2007-01-17 | Laboratorios Del Dr. Esteve, S.A. | Dérivés 4,5-dihydro-1H-pyrazole, leur, préparation et utilisation comme médicaments. |
| WO2007009720A2 (fr) * | 2005-07-15 | 2007-01-25 | Laboratorios Del Dr. Esteve S.A. | Promedicaments de composes de pyrazoline, fabrication et utilisation comme medicaments |
| EP1749821A1 (fr) * | 2005-07-15 | 2007-02-07 | Laboratorios Del Dr. Esteve, S.A. | Sels de dérives pyrazoline, leur préparation et leur utilisation comme medicaments médicaments |
| CA2619480A1 (fr) * | 2005-08-17 | 2007-02-22 | Solvay Pharmaceuticals Gmbh | Methode d'utilisation de composes inhibiteurs du canal du potassium |
| JP4658134B2 (ja) | 2005-10-04 | 2011-03-23 | 田辺三菱製薬株式会社 | 光学活性４−ヒドロキシ−１，２，３，４−テトラヒドロキノリン化合物の製法 |
| AR056560A1 (es) | 2005-10-06 | 2007-10-10 | Astrazeneca Ab | Pirrolopiridinonas como moduladores cb1 |
| KR20080089413A (ko) * | 2005-12-20 | 2008-10-06 | 솔베이 파마슈티칼스 비. 브이 | 카나비노이드 ｃｂ1 수용체 조절자로서의4,5-디하이드로-(1ｈ)-피라졸 유도체 |
| US7763607B2 (en) | 2006-04-27 | 2010-07-27 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators |
| US20070254863A1 (en) * | 2006-04-27 | 2007-11-01 | Jochen Antel | Use of CBx cannabinoid receptor modulators as potassium channel modulators |
| AU2007245733A1 (en) * | 2006-04-27 | 2007-11-08 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising CBX cannabinoid receptor modulators and Potassium channel modulators |
| JP5561720B2 (ja) * | 2006-05-05 | 2014-07-30 | ジェンリン ディスカバリー | 肥満及び糖尿病を含む心臓血管障害を治療するために有用なカンナビノイド受容体アンタゴニスト／インバ−スアゴニスト |
| US7629346B2 (en) | 2006-06-19 | 2009-12-08 | Hoffmann-La Roche Inc. | Pyrazinecarboxamide derivatives as CB1 antagonists |
| US7964728B2 (en) * | 2006-07-06 | 2011-06-21 | Solvay Pharmaceuticals B.V. | Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition |
| RU2009108280A (ru) | 2006-08-08 | 2010-09-20 | Санофи-Авентис (Fr) | Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение |
| US7781593B2 (en) | 2006-09-14 | 2010-08-24 | Hoffmann-La Roche Inc. | 5-phenyl-nicotinamide derivatives |
| AR062907A1 (es) * | 2006-09-22 | 2008-12-17 | Solvay Pharm Bv | Derivados de sulfonilpirazol y sulfonilpirazolincarboxamidina como antagonistas de 5-ht6 |
| US8124634B2 (en) * | 2006-12-18 | 2012-02-28 | 7Tm Pharma A/S | CB1 receptor modulators |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| ES2393885T7 (es) | 2007-06-04 | 2014-01-30 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
| EP2025674A1 (fr) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament |
| US7655685B2 (en) * | 2007-11-02 | 2010-02-02 | Jenrin Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes |
| UY31968A (es) | 2008-07-09 | 2010-01-29 | Sanofi Aventis | Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos |
| AU2009270833B2 (en) | 2008-07-16 | 2015-02-19 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| EP2151234A1 (fr) * | 2008-07-28 | 2010-02-10 | Laboratorios Del. Dr. Esteve, S.A. | Formulation pharmaceutique comprenant un composé récepteur CB1 dans une solution solide et/ou une dispersion solide |
| TW201010981A (en) * | 2008-08-01 | 2010-03-16 | Solvay Pharm Bv | Synthesis of 3,4-diaryl-4,5-dihydro-(1H)-pyrazole-1-carboxamidine derivatives |
| MX2011004258A (es) | 2008-10-22 | 2011-06-01 | Merck Sharp & Dohme | Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos. |
| CA2741672A1 (fr) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Nouveaux agents antidiabetiques utiles avec des derives de benzimidazole cycliques |
| WO2010068601A1 (fr) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant |
| WO2010079241A1 (fr) | 2009-01-12 | 2010-07-15 | Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion | Utilisation d'antagonistes et/ou d'agonistes inverses des récepteurs cb1 pour la préparation de médicaments qui augmentent l'excitabilité des motoneurones |
| SG178880A1 (en) | 2009-08-26 | 2012-04-27 | Sanofi Sa | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
| US8217038B2 (en) | 2009-10-07 | 2012-07-10 | Jenrin Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes |
| CA2786314A1 (fr) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Nouveaux derives benzimidazole cycliques utiles comme agents antidiabetiques |
| WO2011157827A1 (fr) | 2010-06-18 | 2011-12-22 | Sanofi | Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| US8410107B2 (en) | 2010-10-15 | 2013-04-02 | Hoffmann-La Roche Inc. | N-pyridin-3-yl or N-pyrazin-2-yl carboxamides |
| EP2640381A4 (fr) | 2010-11-18 | 2014-05-21 | Jenrin Discovery | Antagonistes/agonistes inverses du récepteur des cannabinoïdes utiles pour le traitement de troubles métaboliques, y compris l'obésité et le diabète |
| US8669254B2 (en) | 2010-12-15 | 2014-03-11 | Hoffman-La Roche Inc. | Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents |
| KR101668514B1 (ko) | 2011-02-25 | 2016-10-21 | 머크 샤프 앤드 돔 코포레이션 | 항당뇨병제로서 유용한 신규 시클릭 아자벤즈이미다졸 유도체 |
| US8846666B2 (en) | 2011-03-08 | 2014-09-30 | Sanofi | Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| EP2683699B1 (fr) | 2011-03-08 | 2015-06-24 | Sanofi | Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation |
| WO2012120057A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, agent pharmaceutique contenant ces composés et leur utilisation |
| US8809324B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
| US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| WO2012120054A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation |
| WO2012120052A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation |
| US8809325B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof |
| US8680131B2 (en) | 2012-07-25 | 2014-03-25 | Jenrin Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers |
| AU2013296420B2 (en) | 2012-08-01 | 2017-12-07 | Lewis And Clark Pharmaceuticals, Inc. | N-alkyl 2-(disubstituted)alkynyladenosine-5-uronamides as A2A agonists |
| JP2015525782A (ja) | 2012-08-02 | 2015-09-07 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 抗糖尿病性三環式化合物 |
| JP6272626B2 (ja) * | 2012-11-13 | 2018-01-31 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | カンナビノイド受容体媒介性化合物 |
| US11155521B2 (en) | 2012-11-13 | 2021-10-26 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Cannabinoid receptor mediating compounds |
| RU2015140066A (ru) | 2013-02-22 | 2017-03-30 | Мерк Шарп И Доум Корп. | Противодиабетические бициклические соединения |
| US9650375B2 (en) | 2013-03-14 | 2017-05-16 | Merck Sharp & Dohme Corp. | Indole derivatives useful as anti-diabetic agents |
| CA2905435A1 (fr) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions utiles pour le traitement de troubles gastro-intestinaux |
| JP2016514671A (ja) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼのアゴニストおよびその使用 |
| US10011637B2 (en) | 2013-06-05 | 2018-07-03 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
| WO2015051496A1 (fr) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Composés tricycliques antidiabétiques |
| EP3140288B1 (fr) * | 2014-05-09 | 2023-01-25 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Dérivés de pyrazole et leur utilisation en tant que médiateurs du récepteur cannabinoïde |
| EP3109237A1 (fr) | 2015-06-22 | 2016-12-28 | AnaMar AB | Nouveaux antagonistes de 5-ht2 |
| WO2018106518A1 (fr) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Composés hétérocycliques antidiabétiques |
| EP4341246A1 (fr) | 2021-05-17 | 2024-03-27 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Approche facile et exempte d'odeur pour convertir des dérivés de sulfonylurée en dérivés de sulfonylurée de chalcogénure |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5591764A (en) * | 1988-09-27 | 1997-01-07 | E. I. Du Pont De Nemours And Company | N-acylated pyrazolines |
| FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
-
2001
- 2001-03-22 CA CA002401832A patent/CA2401832C/fr not_active Expired - Fee Related
- 2001-03-22 RU RU2002128352/04A patent/RU2245878C2/ru not_active IP Right Cessation
- 2001-03-22 UA UA2002108258A patent/UA74367C2/uk unknown
- 2001-03-22 ES ES01915398T patent/ES2272449T3/es not_active Expired - Lifetime
- 2001-03-22 DZ DZ013335A patent/DZ3335A1/fr active
- 2001-03-22 PT PT01915398T patent/PT1268435E/pt unknown
- 2001-03-22 HU HU0204519A patent/HUP0204519A3/hu unknown
- 2001-03-22 DK DK01915398T patent/DK1268435T3/da active
- 2001-03-22 PL PL358101A patent/PL208098B1/pl not_active IP Right Cessation
- 2001-03-22 DE DE60124685T patent/DE60124685T2/de not_active Expired - Lifetime
- 2001-03-22 WO PCT/EP2001/003247 patent/WO2001070700A1/fr active IP Right Grant
- 2001-03-22 AT AT01915398T patent/ATE346047T1/de active
- 2001-03-22 AU AU4250101A patent/AU4250101A/xx active Pending
- 2001-03-22 CN CNB01806910XA patent/CN1205188C/zh not_active Expired - Fee Related
- 2001-03-22 SI SI200130668T patent/SI1268435T1/sl unknown
- 2001-03-22 IL IL15145201A patent/IL151452A0/xx active IP Right Grant
- 2001-03-22 EP EP01915398A patent/EP1268435B1/fr not_active Expired - Lifetime
- 2001-03-22 KR KR1020027012531A patent/KR100800277B1/ko not_active IP Right Cessation
- 2001-03-22 JP JP2001568910A patent/JP2004500401A/ja not_active Withdrawn
- 2001-03-22 MX MXPA02009258A patent/MXPA02009258A/es active IP Right Grant
- 2001-03-22 BR BR0109457-2A patent/BR0109457A/pt not_active Application Discontinuation
- 2001-03-22 SK SK1352-2002A patent/SK287074B6/sk not_active IP Right Cessation
- 2001-03-22 AU AU2001242501A patent/AU2001242501B2/en not_active Ceased
- 2001-03-23 US US09/814,694 patent/US6476060B2/en not_active Expired - Lifetime
-
2002
- 2002-08-22 IL IL151452A patent/IL151452A/en not_active IP Right Cessation
- 2002-09-20 NO NO20024531A patent/NO324173B1/no not_active IP Right Cessation
-
2003
- 2003-06-25 HK HK03104555.6A patent/HK1052349B/zh not_active IP Right Cessation
-
2007
- 2007-01-30 CY CY20071100124T patent/CY1105967T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO324173B1 (no) | 4,5-dihydro-1H-pyrazolderivater med CB1-antagonistaktivitet, fremgangsmate til fremstilling derav, anvendelse derav til fremstilling av et medikament, en farmasoytisk sammensetning og mellomprodukter | |
| AU2001242501A1 (en) | 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity | |
| EP1373216B1 (fr) | Derives de 4,5-dihydro-1h-pyrazole ayant une activite d'antagoniste de cb 1 | |
| CA2442245C (fr) | Derives 4,5-dihydro-1h-pyrazole presentant une puissante activite antagoniste du recepteur cb1 | |
| AU2002333852B2 (en) | Novel 4,5-dihydro-1H-pyrazole derivativeshaving CB1-antagonistic activity | |
| AU2002256690A1 (en) | 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity | |
| ZA200207303B (en) | 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |